A new day dawns: women without oestrogen or is a balance best?
AUTOR(ES)
Jordan, V Craig
FONTE
BioMed Central
RESUMO
Building on the 30-year success story with tamoxifen, the question now is whether one agent can be used for treatment and prevention or should new medicines be targeted to specific applications? The early results with anastrozole suggest it could replace tamoxifen for treatment and should be tested as a preventive. Unfortunately, long-term testing of aromatase inhibitors will be required to avoid concerns about osteoporosis, Alzheimer's disease and coronary heart disease. Most importantly, the knowledge gained with tamoxifen has resulted in a new generation of selective oestrogen receptor modulators that can be used to prevent osteoporosis, breast cancer and uterine cancer. It is now clear that strategies utilising aromatase inhibitors and selective oestrogen receptor modulators will provide much needed options for individualised treatments.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=137939Documentos Relacionados
- Drug treatment of Parkinson's disease: is "polypharmacy" best?
- Should doctors intentionally do less than the best?
- Oestrogen only arm of women's health initiative trial is stopped
- Self-Monitoring with or Without Telemonitoring: Is a New Time for Diagnosis and Management Hypertension?
- Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
